

FOLEY LARDNER

ATTORNEYS AT LAW

11250 EL CAMINO REAL, SUITE 200

SAN DIEGO, CA 92130

P.O. BOX 80278

SAN DIEGO, CALIFORNIA 92138-0278

TELEPHONE: 858.847.6700

FACSIMILE: 858.792.6773

WWW.FOLEYLARDNER.COM

FAX RECEIVED

FEB 29 12:00:02

GROUP 1600

CONFIDENTIAL

FACSIMILE TRANSMISSION**FAX RECEIVED****Total # of Pages 16 (including this page)****MAR 01 2002**

TO:	PHONE #:	FAX #:
TC1600 U.S. Patent & Trademark Office		GROUP 1600 703/872-9306

From : Barry S. Wilson**Email Address :** bwilson@foleylaw.com**Sender's Direct Dial :** 858.847.6722**Date :** February 28, 2002**Client/Matter No :** 068904-0302**User ID No :** 3067**MESSAGE:****Re:** U.S. Patent Application Serial No.: 09/005,318**Filed:** January 9, 1998**Title:** NOVEL EPITHELIAL TISSUE TARGETING AGENT**Inventor(s):** Hein et al.**Docket No.:** EPI3004B

PLEASE SEE THE ATTACHED AMENDMENT FILING IN CONNECTION WITH THE ABOVE-REFERENCED PATENT APPLICATION.

If there are any problems with this transmission or if you have not received all of the pages, please call 858.847.6700.

Operator:	Time Sent:	Return Original To: Pridge McDougall
------------------	-------------------	--

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

FAX RECEIVED

FEB 28 2002

Atty. Dkt. No. EPI3004B
(formerly 310098.401C1)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Mitch B. Hein et al.

Title: NOVEL EPITHELIAL TISSUE
TARGETING AGENT

Appl. No.: 09/005,318

Filing Date: 01/09/1998

Examiner: D. Romeo

Art Unit: 1646

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office, Washington, D.C. on the date below.	
Pridge McDougall	(Printed Name)
<i>Pridge McDougall</i>	(Signature)
February 28, 2002	(Date of Deposit)

AMENDMENT TRANSMITTALCommissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- [X] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- [] Small Entity statement is enclosed.
- [X] The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	31	41	0	x \$18.00	\$0.00
Independents:	1	9	0	x \$84.00	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$280.00	\$0.00
CLAIMS FEE TOTAL:					\$0.00

- [X] Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

Atty. Dkt. No. EPI3004B
(formerly 310098.401C1)

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$400.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$920.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,440.00	\$0.00
<input checked="" type="checkbox"/>	Extension for response filed within the fifth month:	\$1,960.00	\$1,960.00
EXTENSION FEE TOTAL:			\$1,960.00
CLAIMS AND EXTENSION FEE TOTAL:			\$1,960.00
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$980.00
TOTAL FEE:			\$980.00

- ☒ Please charge Deposit Account No. 50-0872 in the amount of \$980.00. A duplicate copy of this transmittal is enclosed.
- ☐ A check in the amount of \$980.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.


Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date: February 28, 2002

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6722
Facsimile: (858) 792-6773

By



Barry S. Wilson
Attorney for Applicant
Registration No. 39,431

Atty. Dkt. No. EPI3004B
(formerly 310098.401C1)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Hein et al.
Title: NOVEL EPITHELIAL TISSUE
TARGETING MOLECULE
Appl. No.: 09/005,318
Filing Date: 01/09/1998
Examiner: D. Romeo
Art Unit: 1647

CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office, Washington, D.C. on the date below. <u>Pridge McDougall</u> (Printed Name) <u>Pridge McDougall</u> (Signature) <u>February 28, 2002</u> (Date of Deposit)

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is responsive to the Office Action mailed August, 29, 2001.
Accompanying the Amendment is a request for an extension of time of five months to
reply to the Office Action. Accordingly, this Amendment is timely filed.

Please amend the application as follows:

In the Claims:

Please cancel claims 1-28, 30, 31, and 36-41 without prejudice or disclaimer.

Please add new claims 42 to 72 as follows:

42. (New) A composition for delivery of a biological agent to a basolateral factor
of an epithelial surface, said composition comprising a targeting molecule linked to at least
one biological agent, wherein said targeting molecule comprises a J chain or portion
thereof that specifically binds to a basolateral factor, wherein said targeting molecule does
not comprise a full-length immunoglobulin, and wherein said biological agent is not native
to the targeting molecule and is not iodine.

43. (New) The composition of claim 42 wherein said targeting molecule is
covalently linked to said at least one biological agent.